WHO ICTRP trial
Phase III randomised, double-blind, placebo-controlled trial of Gefitinib…
ISRCTN29580179 · International Standard Randomised Controlled Trial Number (ISRCTN) · Not Recruiting
Key facts
| Trial ID | ISRCTN29580179 |
|---|---|
| Public title | Phase III randomised, double-blind, placebo-controlled trial of Gefitinib (Iressa®) versus placebo in Oesophageal Cancer progressing after chemotherapy |
| Scientific title | Phase III randomised, double-blind, placebo-controlled trial of Gefitinib (Iressa®) versus placebo in Oesophageal Cancer progressing after chemotherapy |
| Primary sponsor | University of Oxford (UK) |
| Registry | International Standard Randomised Controlled Trial Number (ISRCTN) |
| Recruitment status | Not Recruiting |
| Study type | Interventional |
| Phase | Not Specified |
| Countries | United Kingdom |
| Conditions | Oesophageal cancer Cancer Oesophageal cancer |
| Interventions | 450 (225 per arm) patients will be randomised to either Gefitinib 500 mg (Iressa®) or placebo. As of October 2009: recruiting Duration of the interventions: The trial will close 6 months after the end of recruitment or when 389 events have… |
| Registration date | Nov 14, 2007 |
| Target size | 450 |
| Secondary IDs | 2007-005391-13;NCT01243398;OCTO_005 |
| Registry page | isrctn.com |
At a glance
- Yes Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: